abstract |
This disclosure relates to a family of pyrrole derivatives of formula I, wherein R1, R2, R3 and R4 are as disclosed in the specification. The family also include its tautomeric forms, stereoisomers and pharmaceutically acceptable salts. The disclose also relates to their use in preventing or treating a disease or disorder mediated by nicotinic acetylcholine receptors. These conditions include attention deficit hyperactivity disorders, schizophrenia, Alzheimer’s disease, Parkinson’s dementia, vascular dementia or dementia associated with Lewy bodies and traumatic brain injury. Examples of compounds include: 4-(5-(2,2-dimethylchroman-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide; 4-(5-(8-fluoro-4,4-dimethylchroman-6-yl)-2-methyl-3-propionyl-1H-pyrrol-lyl)benzenesulfonamide; 4-(5-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide; 4-(5-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide; 4-(5-(4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide; 4-(2-methyl-3-propionyl-5-(3H-spiro[benzo[b][1,4]dioxine-2,1’-cyclopropan]-7-yl)-1H-pyrrol-1-yl)benzenesulfonamide; 4-(2-methyl-3-propionyl-5-(3 H-spiro[benzo[b][1,4]dioxine-2,1’-cyclopropan]-6-yl)-1H-pyrrol-1-yl)benzenesulfonamide; |